Cargando…

Neoadjuvant Nivolumab and Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Retrospective Study

BACKGROUND: Patients with locally advanced (stage III) non-small cell lung cancer (NSCLC) demonstrate broad anatomic heterogeneity with modest survival benefits. Immune checkpoint inhibitors (ICIs) have shown survival benefit in metastatic NSCLC. We conducted this study to evaluate the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhai, Hengyu, Li, Wenhai, Jiang, Kun, Zhi, Yanan, Yang, Zhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841324/ https://www.ncbi.nlm.nih.gov/pubmed/35173485 http://dx.doi.org/10.2147/CMAR.S344343

Ejemplares similares

A case of locally advanced gastric cancer treated with nivolumab, trastuzumab, plus chemotherapy in a neoadjuvant setting
por: Jiang, Shi-Yu, et al.
Publicado: (2019)

Neoadjuvant immunotherapy combined with chemotherapy for local advanced non-small cell lung cancer: a case report
por: Yang, Jie, et al.
Publicado: (2021)

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
por: Reuss, Joshua E, et al.
Publicado: (2020)

Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer
por: Liang, Hengrui, et al.
Publicado: (2021)

Neoadjuvant immune checkpoint inhibitor treatment + chemotherapy (vs. chemotherapy alone) for locally advanced non‑small cell lung cancer: A retrospective cohort study
por: Yang, Yi, et al.
Publicado: (2023)

Uniportal video-assisted thoracoscopic surgery following neoadjuvant chemotherapy for locally-advanced lung cancer
por: Yang, Zhiqiang, et al.
Publicado: (2018)

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
por: Yang, Szu-Chun, et al.
Publicado: (2021)

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
por: Cascone, Tina, et al.
Publicado: (2023)

A Retrospective Study of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
por: Wang, Yajing, et al.
Publicado: (2020)

Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
por: Rosner, Samuel, et al.
Publicado: (2023)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

Complete response in patients with locally advanced rectal cancer after neoadjuvant treatment with nivolumab
por: Zhang, Jianwei, et al.
Publicado: (2019)

Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review
por: Yin, Cunli, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer
por: Tong, Xie, et al.
Publicado: (2023)

Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy
por: Li, Luzhen, et al.
Publicado: (2022)

Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy
por: Nishimura, Tomoka, et al.
Publicado: (2022)

Neoadjuvant therapy for locally advanced non-small cell lung cancer: TKIs or immunotherapy?
por: Zhang, Zhenyang, et al.
Publicado: (2020)

Neoadjuvant chemotherapy for locally advanced cervical cancer
por: Iwata, Takashi, et al.
Publicado: (2016)

Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma
por: Velandia, Carlos, et al.
Publicado: (2018)

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer
por: Papaccio, Federica, et al.
Publicado: (2020)

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
por: Provencio, Mariano, et al.
Publicado: (2022)

Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer
por: Dai, Jie, et al.
Publicado: (2022)

Before or After: Evolving Neoadjuvant Approaches to Locally Advanced Non-Small Cell Lung Cancer
por: Lewis, Jennifer, et al.
Publicado: (2018)

Neoadjuvant Therapy and Factors Influencing Survival in Locally Advanced Non-Small Cell Lung Cancer
por: Ebinç, Senar, et al.
Publicado: (2023)

Retrospective analysis of long‐term survival factors in patients with advanced non‐small cell lung cancer treated with nivolumab
por: Murakami, Yusuke, et al.
Publicado: (2022)

Initial experience of video-assisted thoracic surgery lobectomy after neoadjuvant chemotherapy plus toripalimab in a patient with locally advanced non-small cell lung cancer: a case report
por: Li, Wei, et al.
Publicado: (2022)

The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer
por: Body, Amy, et al.
Publicado: (2021)

Neoadjuvant therapy in localized non-small cell lung cancer: can we do better than chemotherapy?
por: Chau, Brittney, et al.
Publicado: (2019)

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
por: Ho, Won Jin, et al.
Publicado: (2021)

A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer
por: Chen, Shuo, et al.
Publicado: (2018)

Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
por: Le, Alexander D, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
por: Hu, Huabin, et al.
Publicado: (2020)

Nivolumab in Metastatic Non–Small Cell Lung Cancer
por: Deel, Andrea
Publicado: (2016)

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
por: Zhao, Ze-Rui, et al.
Publicado: (2021)

Tracking the dropout patients of neoadjuvant chemotherapy with locally advanced oral cavity cancer
por: Fu, Jin-Ye, et al.
Publicado: (2021)

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
por: Kazandjian, Dickran, et al.
Publicado: (2016)

Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature
por: Franzi, Sara, et al.
Publicado: (2022)

Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
por: Hu, Shanlian, et al.
Publicado: (2023)

Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study
por: Yano, Yukihiro, et al.
Publicado: (2018)

Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer
por: Lin, Huaqin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tkgmiem8qksr6a5ab4a71mqhct